Clinical Trial Update: Study To Describe The Safety, Tolerability, And Immunogenicity Of Bivalent Rlp2086 Vaccine In Laboratory Workers ≥18 To ≤65 Years Of Age [Phase 2]

View source ↗

Summary

Phase 2 trial update for a bivalent vaccine (Rlp2086) assessing safety, tolerability, and immunogenicity in laboratory workers aged 18-65, completed with result…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Meningitis
• Meningococcal Meningitis
• Serogroup Meningococcal Disease

Drugs mentioned

• Rlp2086

Snippet

Sponsor: Pfizer | Conditions: Meningitis, Meningococcal, Serogroup B | Phase 2 | Status: COMPLETED | Results posted: 2015-03-09